FOLH1 and neoplasm: The glutamate-urea-lysine-based PSMA ligand structure optimization performed in our study showed that addition of the fluorophore/photosensitizer (IRDye700DX) and additional negative charges in the linker or chelator part of the ligand, significantly improved tumor targeting.